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ABSTRACT
Neuroimmunology has led to advanced diagnostics of previously cryptic disorders, using autoantibody testing against 
neurological targets. Neuropsychiatric syndromes and autoimmune encephalitis can now be routinely diagnosed using 
specialized antibody tests such as immunofluorescence and immunoblot assays in specialized laboratories. This helps 
in early and accurate diagnosis, leading to favorable patient prognosis. Here, we briefly review the diagnostics for 
Neuroimmunologic and related disorders including autoimmune encephalitis, demyelinating diseases, neuropathies, 
paraneoplastic syndromes, stiffperson syndrome, inflammatory myopathies as well as Alzheimer’s disease.
R E V I E W  A R T I C L E
INTRODUCTION
Autoantibody testing is becoming increasing relevant 
for Neurologists due to the rapidly growing list of novel 
autoantibodies against neurological targets. These are 
detectable by several major methods: 
Immunofluorescence (IIFT), Immunoblot (IB), 
Bioluminescence (BL) and ELISA (Tozzoli et al., 2002; 
Westgeest et al., 1988). IIFT is the GOLD standard for 
the diagnosis of auto-antibodies (Meroni and Schur, 
2010; Tozzoli et al., 2002; Westgeest et al., 1988). IB 
is a very sensitive test designed as a modification of the 
classic western blot on a pre-manufactured strip 
(Westgeest et al., 1988). IB tests have the advantage 
of being able to detect multiple specific auto-antibodies 
in a single test. Due to their high sensitivity, low titre 
results are prone to false positivity and clinical 
correlation is advised. ELISA is a more specific, but less 
sensitive test than IB (Copple et al., 2011; Meroni and 
Schur, 2010). ELISA is useful when high titre 
antibodies of unique specificity are present. BL is more 
sensitive than ELISA and has good specificity but has 
limited availability. In this primer, we briefly review the 
various Neuroimmunologic disorders and their 
diagnostic antibody testing for the busy Neurologist. 
AUTOIMMUNE ENCEPHALITIS
Autoimmune encephalitis is treatable and patients 
frequently present with acute or subacute onset of any 
of the following signs: seizures, psychosis, confusion, 
dementia, abnormal movements or neuropsychiatric 
manifestations (Shin et al., 2017). MRI brain and CSF 
analysis may be normal or more typically, show subtle 
abnormalities such as increased protein and 
leukocytosis. Several antibodies are detectable in 
autoimmune encephalitis by an IIFT based assay in 
serum or CSF, with over 85% sensitivity. These include 
antibodies against NMDA, AMPA, GABA receptors, 
DPPX, LGI1 and CASPR2. As shown in Figure 1, 
neuronal antigens are of functional significance. 
Binding of auto-antibodies results in internalization and 
degradation of these cell surface receptors and 
proteins, leading to neuronal dysfunction. NMDA and 
AMPA are involved in long term potentiation and 
depression and their disruption leads to cognitive 
impairment, neuropsychiatric manifestations and 
seizures (Shin et al., 2017; Joubert and Honnorat. 
2015). LGI1 and CASPR2 are part of the 
voltage-gated-potassium-channel complex (VGKC) on 
the pre-synaptic membrane in glutamergic neurons 
(Figure 1). Antibody binding to LGI uncouples AMPA 
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receptors and leads to their endocytosis and functional 
disruption. Anti-GABA antibodies, if present in high 
titers, lead to seizures and encephalopathy in 
concordance with GABA disinhibition. Overlap 
syndromes with NMDA-receptor and anti-GAD 
antibodies also exist with variable symptomatology 
(Joubert and Honnorat. 2015). 
DEMYELINATING DISEASES
Neuro-myelitis Optica Spectrum Disorders (NMOSD) 
are a differential diagnosis in multiple sclerosis, 
transverse myelitis, optic neuritis and investigation of 
CNS lesions (Dos Passos et al., 2018). NMOSD 
typically suffer transverse myelitis or optic neuritis and 
sometimes may also develop cerebral lesions. 
Anti-Aquaporin-4 (AQP4-Ab) antibodies are a hallmark 
of NMO and are detectable in blood with 80% 
sensitivity and nearly 100% specificity using IIFT (Figure 
2). Antibodies against myelin oligodendrocyte 
glycoprotein (MOG) are associated with better 
prognosis of acute disseminated encephalomyelitis 
(ADEM) and are also found in 25% of AQP4-Ab 
negative NMOSD (Dos Passos et al., 2018). Both these 
antibodies are useful in diagnosing the underlying 
cause of ADEM and Optic neuritis. NMOSD are 
frequently misdiagnosed as isolated transverse myelitis 
or optic neuritis or multiple sclerosis. NMOSD are 
treatable with long term immunomodulation. 
NEUROPATHIES
Common forms of acute and peripheral neuropathies 
are now being recognized as autoimmune in etiology 
and many are responsive to treatment if diagnosed. 
Anti-ganglioside antibodies have been found in 
autoimmune neuropathies, especially in axonal variants 
of Guillain-Barré syndrome (GBS), acute motor axonal 
neuropathy (AMAN) and acute motor-sensory 
neuropathy (AMSAN), chronic inflammatory 
demyelinating polyneuropathies (CIDP) and Miller 
Fisher syndrome and multifocal motor neuropathy 
(MMN) (Plomp and Willison.2009). The following 
antibodies are part of the IB assay for neuropathies: 
GM1, GM2, GM3, GD1a, GD1b, GT1b, GQ1b (Plomp 
and Willison.2009).  Approximately 60% of patients 
with GBS have anti-ganglioside antibodies in sera 
during the acute clinical phase of the disease.
Recently, novel auto-antibodies were found in CIDP and 
GBS, directed against membrane proteins at and 
around the nodes of Ranvier (Burnor et al. 2018). 
Prominent amongst these were auto-antibodies against 
paranodal proteins neurofascin-155 (NF155), 
contactin-1 (CNTN1) and Contactin-associated protein 
1 (Caspr) (Doppler et al. 2016; Manso et al. 2016). 
Caspr is attached to NF155 and CNTN1. Autoimmunity 
against these proteins is most commonly mediated by 
IgG4 with a severe phenotype resistant to IV 
immunoglobulin (IVIG) treatment but responsive to 
Rituximab (Burnor et al. 2018).
PARANEOPLASTIC SYNDROMES (PNS)
PNS are autoimmune mediated complications of 
cancer. These can present when cancer is small and 
curable and sometimes years before appearance of 
malignancy, therefore diagnosis allows significant 
opportunity for early therapeutic intervention. PNS may 
present with cerebellar degeneration (subacute), limbic 
encephalitis, brainstem encephalitis, and sensory 
neuronopathy (Höftberger et al., 2015). In PNS, the 
tumor cells express antigens that normally only occur in 
neurons, inducing an auto-antibody response leading 
to neuronal injury. PNS develop in ~15% of malignant 
cancers, occurring most frequently in small-cell lung 
carcinoma, neuroblastoma, thymoma, and cancers of 
the ovary, breast, uterus and testis. Onco-neuronal 
antibodies in PNS are directed against intracellular 
neuronal antigens: Amphiphysin, CV2, PNMA2/Ta, 
Ri/Anna2, Yo/Pca-1, Recoverin, Hu/Anna, SOX, Titin 
(Höftberger et al., 2015). A positive result has a high 
probability of a tumor. In concordance with clinical 
data, detection of anti-neuronal antibodies is 
considered sufficient for a definitive diagnosis of PNS. 
STIFF-PERSON SYNDROME (SPS)
SPS is a rare neurological disease, which can be 
paraneoplastic or non-paraneoplastic in origin. The 
disease manifests with severe progressive muscle 
stiffness, typically in the spine and lower extremities 
and may be confused with Parkinson’s Disease. 
Paraneoplastic cases are associated with antibodies 
against amphiphysin. Non-paraneoplastic cases are 
characterised by autoantibodies against glutamate acid 
decarboxylase (GAD), which are found in 60-90% of 
patients (Rakocevic et al., 2012). However, anti-GAD 
antibodies are not specific markers for stiff-person 
syndrome as they also occur in other neuronal diseases 
and, in particular, diabetes mellitus type I, albeit in 
lower titres (Rakocevic et al., 2012).
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MYOSITIS
Differentiating inflammatory from degenerative 
myopathies is a challenge at initial presentation. 
Moreover the clinical spectrum of several inflammatory 
myopathies also overlaps making exact diagnosis 
difficult. IB based assay for myositis can detect a range 
of antibodies to accurately diagnose inflammatory 
myositis which help in prognosis and therapeutics 
(Figure 3). Antibodies directed against MDA5, Mi-2, 
SRP and tRNA synthetases (OJ, EJ, PL-12, PL-7, Jo-1), 
PMScl100, Ku antigens can be tested in a single blood 
test using the IB assay. MDA5 is a special syndrome 
resembling SLE and dermatomyositis (DRM) with 
rapidly progressive respiratory failure (Saeed, 2017). 
TIF1γ is associated with DRM with ~ 60% frequency of 
malignancy. Both MDA5 and TIF1γ therefore require 
urgent diagnosis (Betteridge et al., 2011).
ALZHEIMER’S DISEASE AND DEMENTIA 
Though dementias are neurodegenerative disorders, 
there is evidence that they may be a consequence of 
immune mediated injury as well (Long and Day, 2018). 
Furthermore, it was recently shown in a large study of 
about 0.8 million patients that autoimmune diseases 
increase risk of dementia and Alzheimer’s Disease (AD) 
(Li et al, 2018). Therefore early detection of AD is 
important. AD is the most common form of Dementia 
and affects 10% of population above 65 years of age. 
Majority of patients are left undiagnosed which is 
unfortunate as now there is treatment available to slow 
down the progression of dementia and improve 
cognition and quality of life. Clinical diagnosis is 
unreliable. The neuropathology of AD starts decades 
before the onset of clinical disease and is reflected in 
the concentrations of beta- amyloid 1-42 and total Tau 
protein in the CSF.
Beta amyloid alone and tau alone are sensitive but not 
specific for AD but when both assays are used together, 
they greatly improve sensitivity and specificity for 
diagnosis of AD.  In AD the CSF beta-amyloid 1-42 
levels are low (<50%) and CSF total Tau protein is high 
(>300%), and this combination forms the "AD 
signature" (Blennow et al., 2015). These changes in 
beta- amyloid 1-42 and total Tau protein levels occur in 
the preclinical phase and persist through the disease 
course and therefore are an early finding to assist 
diagnosis of AD. Low beta-amyloid 1-42 and high total 
Tau protein levels (AD Signature) used together may 
allow discrimination from healthy controls with level of 
sensitivity and specificity over 85% (Blennow et al., 
2015). 
CONCLUSIONS
Neuroimmunology has emerged as a major 
subspecialty of Neurology overlapping significantly with 
Rheumatology (Saeed and Ahmad, 2017). 
Neuropsychiatric syndromes and autoimmune 
encephalitis can now be routinely diagnosed using 
specialized antibody tests such as IIFT and IB assays in 
specialized laboratories. This helps in early and 
accurate diagnosis which allows early institution of 
immunomodulatory treatments, making a marked 
difference in patient prognosis. 
 
Figure 1. Physiological functioning of GABAergic 
and Glutamatergic neurons
This figure shows the normal functioning of 
variousreceptors and proteins whose disruption by 
auto-antibodies leads to autoimmune encephalitis
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Figure 2. Immunofluorescence testing for autoimmune neurologic disorders
Photographs of IIFT in patients with NMOSD (AQP4 antibodies) and autoimmune 
encephalitis (anti-GABA and anti-NMDA antibodies).
Figure 3. Immunoblot for inflammatory myositis
Immunoblot scan (EUROIMMUN) of a patient with inflammatory myopathy. 
Multiple antibodies are positive including Mi-2a, Mi-2b and SRP.
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